Skip to main content
  • More from ADA
    • Diabetes
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care
  • Subscribe
  • Log in
  • My Cart
  • Follow ada on Twitter
  • RSS
  • Visit ada on Facebook
Diabetes Care

Advanced Search

Main menu

  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • Special Article Collections
    • ADA Standards of Medical Care
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • Special Article Collections
    • ADA Standards of Medical Care
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Journal Policies
    • Instructions for Authors
    • ADA Peer Review
  • More from ADA
    • Diabetes
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care

User menu

  • Subscribe
  • Log in
  • My Cart

Search

  • Advanced search
Diabetes Care
  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • Special Article Collections
    • ADA Standards of Medical Care
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • Special Article Collections
    • ADA Standards of Medical Care
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Journal Policies
    • Instructions for Authors
    • ADA Peer Review
Original Research

Additional Use of Glycated Hemoglobin for Diagnosis of Type 2 Diabetes in People Undergoing Coronary Angiography Reveals a Subgroup at Increased Cardiovascular Risk

  1. Guenther Silbernagel, MD1,2,
  2. Marcus E. Kleber, PHD1,3,
  3. Tanja B. Grammer, MD4,
  4. Bernhard R. Winkelmann, MD5,
  5. Bernhard O. Boehm, MD6 and
  6. Winfried März, MD3,4,7⇓
  1. 1Ludwigshafen Risk and Cardiovascular Health Study Nonprofit LLC, Freiburg, Germany
  2. 2Division of Endocrinology, Diabetology, Nephrology, Vascular Disease, and Clinical Chemistry, Department of Internal Medicine, Eberhard-Karls-University Tübingen, Tübingen, Germany
  3. 3Synlab Center of Laboratory Diagnostics Heidelberg, Heidelberg, Germany
  4. 4Mannheim Institute of Public Health, Social and Preventive Medicine, Mannheim Medical Faculty, University of Heidelberg, Mannheim, Germany
  5. 5Cardiology Group Frankfurt-Sachsenhausen, Frankfurt, Germany
  6. 6Division of Endocrinology, Department of Internal Medicine, Ulm University, Ulm, Germany
  7. 7Clinical Institute of Medical and Chemical Laboratory Diagnostics, Medical University of Graz, Graz, Austria
  1. Corresponding author: Winfried März, winfried.maerz{at}synlab.de.
Diabetes Care 2011 Nov; 34(11): 2471-2473. https://doi.org/10.2337/dc11-1046
PreviousNext
  • Article
  • Figures & Tables
  • Info & Metrics
  • PDF
Loading

This article has a correction. Please see:

  • Erratum - December 01, 2011

Abstract

OBJECTIVE To study the prognosis of people with newly diagnosed type 2 diabetes as per the American Diabetes Association (ADA) 2010 definition but without diabetes as per the ADA 2009 definition.

RESEARCH DESIGN AND METHODS A total of 2,002 participants of the Ludwigshafen Risk and Cardiovascular Health (LURIC) study without a history of diabetes were studied.

RESULTS During the follow-up of a mean duration ± SD of 7.7 ± 2.0 years, 346 people died (202 cardiovascular deaths). Subjects with type 2 diabetes as per the ADA 2009 definition (n = 468) had significantly increased all-cause and cardiovascular mortality compared with people without diabetes as per the ADA 2010 definition (both P ≤ 0.003). Subjects with type 2 diabetes as per the ADA 2010 definition but without diabetes as per the ADA 2009 definition (n = 150) were at significantly increased risk to die of cardiovascular diseases (P = 0.029).

CONCLUSIONS Use of the ADA 2010 diabetes definition may be instrumental in improving cardiovascular risk stratification in people undergoing coronary angiography.

According to the 2009 guidelines of the American Diabetes Association (ADA), subjects with increased fasting glucose (≥126 mg/dL) and/or postchallenge glucose (≥200 mg/dL) are diagnosed with diabetes (1). Using the ADA 2010 criteria, subjects with isolated elevation of glycated hemoglobin ≥6.5% (fasting glucose <126 mg/dL, postchallenge glucose <200 mg/dL) are also considered diabetic individuals (2).

Glycated hemoglobin has been associated with macrovascular disease (3–8). Of particular interest, recent data from the Atherosclerosis Risk in Communities (ARIC) study and the Ludwigshafen Risk and Cardiovascular Health (LURIC) study have shown that glycated hemoglobin is a better predictor for all-cause and cardiovascular mortality than fasting glucose (9,10).

The objective of the present work in 2,002 LURIC participants was to analyze whether subjects with newly diagnosed type 2 diabetes as per the ADA 2010 definition who would not have received the diagnosis as per the ADA 2009 definition are at increased risk of death from any cause and from cardiovascular diseases (10,11).

RESEARCH DESIGN AND METHODS

LURIC is a cross-sectional and prospective clinical trial that was designed to investigate cardiovascular risk factors. A total of 3,316 white subjects were recruited between July 1997 and January 2000 at the Ludwigshafen Heart Center in southwestern Germany (10,11). All participants underwent coronary angiography. The precise inclusion/exclusion criteria have been previously described (10,11). For the present analyses, subjects with known diabetes or incomplete determination of the glucometabolic phenotype (missing 75-g oral glucose tolerance test despite fasting glucose <126 mg/dL) were additionally ruled out. Information on the cause of death was missing for 11 decedents. These people were excluded when data on cardiovascular mortality were analyzed. The study was approved by the ethics committee at the Ärztekammer Rheinland-Pfalz and was conducted in accordance with the Declaration of Helsinki. Informed written consent was obtained from all participants (10). Diabetes was diagnosed according to the 2009 and 2010 criteria of the ADA (1,2). The follow-up for all-cause and cardiovascular mortality had a mean duration ± SD of 7.7 ± 2.0 years.

Laboratory analyses

The laboratory methods have been reported previously (10,11). Glucose was measured enzymatically on a Hitachi 717 analyzer (Roche, Mannheim, Germany). Glycated hemoglobin was measured with an immunoassay (hemoglobin A1c UNIMATE 5; Hoffmann-LaRoche, Grenzach-Whylen, Germany).

Statistical analysis

The baseline clinical and biochemical characteristics are presented for three groups: group A, subjects without diabetes as per the ADA 2010 definition (without diabetes); group B, subjects with type 2 diabetes as per the ADA 2010 definition but without diabetes as per the ADA 2009 definition (T2DM ADA 2010); and group C, subjects with type 2 diabetes as per the ADA 2009 definition (T2DM ADA 2009). Categorical data are expressed as numbers and percentages. In the case of continuous variables, we report means with SDs or medians with interquartile ranges. P values for differences in baseline characteristics among the three groups were calculated with the χ2 test for categorical data and with ANOVA for continuous variables. Triglycerides and insulin were transformed logarithmically before being used in parametric statistical procedures. The Cox proportional hazards model was used to test the relationships of the three groups with all-cause and cardiovascular mortality. Two predefined models of adjustment were used (model 1: univariate; model 2: adjusted for sex, age, BMI, hypertension, smoking, glomerular filtration rate, triglycerides, LDL cholesterol, and HDL cholesterol). The results are presented as hazard ratios with 95% CIs. All statistical tests were two-sided and P < 0.05 was considered significant. The SPSS 15.0 statistical package (SPSS Inc., Chicago, IL) was used.

RESULTS

The clinical and biochemical characteristics of the study participants and data on mortality are shown in Table 1. A total of 346 (17.3%) deaths occurred during the follow-up. Among these, 202 (58.4%) were accounted for by cardiovascular diseases. Compared with subjects without diabetes, people with T2DM ADA 2009 (hazard ratio 2.02 [95% CI 1.61–2.53]; P < 0.001) and those with T2DM ADA 2010 (1.54 [1.05–2.26]; P = 0.028) had increased all-cause mortality. After multivariate adjustment, this association remained significant for individuals with T2DM ADA 2009 (1.62 [1.28–2.04]; P < 0.001) but turned insignificant for those with T2DM ADA 2010 (1.34 [0.91–1.97]; P = 0.141). There was no significant difference in all-cause mortality between subjects with T2DM ADA 2009 and people with T2DM ADA 2010 (P = 0.360, model 2). Compared with subjects without diabetes, subjects with T2DM ADA 2009 (1.99 [1.48–2.69]; P < 0.001) and those with T2DM ADA 2010 (1.98 [1.25–3.13]; P = 0.003) more frequently died of cardiovascular diseases. These associations remained significant after multivariate adjustment for both subjects with T2DM ADA 2009 (1.62 [1.18–2.21]; P = 0.003) and subjects with T2DM ADA 2010 (1.67 [1.05–2.65]; P = 0.029). There was no significant difference in cardiovascular mortality between subjects with T2DM ADA 2009 and subjects with T2DM ADA 2010 (P = 0.894, model 2).

View this table:
  • View inline
  • View popup
Table 1

Baseline characteristics according to diabetes definition

CONCLUSIONS

The current study shows that LURIC participants with newly diagnosed T2DM ADA 2010 have increased cardiovascular mortality compared with those without diabetes. Of importance, there were no differences in mortality rates for cardiovascular disease between LURIC participants with T2DM ADA 2009 and those with T2DM ADA 2010. In agreement, subjects with T2DM ADA 2009 and people with T2DM ADA 2010 had a similar cardiovascular risk factor profile.

There is broad evidence that type 2 diabetes will increase the risk of cardiovascular death (12–14). Thus far, only subjects with elevated fasting or postchallenge glucose were diagnosed with diabetes (1). However, fasting and postchallenge glucose have high intraindividual variability (15). Hence, the sensitivity of these tests to select subjects with disturbance of glucose metabolism is not optimal.

Our data support that the use of glycated hemoglobin at a cut point of ≥6.5% as an additional criterion for the diagnosis of diabetes may improve cardiovascular risk stratification in subjects referred for coronary angiography. Future studies should attempt to answer the question whether measurement of glycated hemoglobin will obviate the need for oral glucose tolerance testing.

Acknowledgments

B.O.B. has received grants from the Deutsche Forschungsgemeinschaft (GrK 1041) and the Centre of Excellence “Metabolic Diseases” Baden-Wuerttemberg. The LURIC study has received funding through the 6th Framework Program (integrated project Bloodomics, Grant LSHM-CT-2004-503485) and the 7th Framework Program (integrated project Atheroremo, Grant 201668) of the European Union.

No potential conflicts of interest relevant to this article were reported.

G.S. performed the statistical analysis and wrote the manuscript. M.E.K. performed the statistical analysis. T.B.G. contributed to the interpretation of results and reviewed the manuscript. B.R.W. designed the study. B.O.B. and W.M. designed the study and wrote the manuscript. All authors have read and approved the manuscript as submitted and take responsibility for the content of the article.

Parts of this study were presented in abstract form at the 79th Congress of the European Atherosclerosis Society, Gothenburg, Sweden, 26–29 June 2011.

The authors are grateful to the participants of the LURIC study; without their collaboration, this article would not have been written. The authors also thank the LURIC study team either temporarily or permanently involved in patient recruitment and sample and data handling, the laboratory staff at the Ludwigshafen General Hospital, and the Universities of Freiburg and Ulm.

  • Received June 2, 2011.
  • Accepted August 15, 2011.
  • © 2011 by the American Diabetes Association.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details.

References

  1. ↵
    American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2009;32(Suppl. 1):S62–S67pmid:19118289
    OpenUrlFREE Full Text
  2. ↵
    American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2010;33(Suppl. 1):S62–S69pmid:20042775
    OpenUrlFREE Full Text
  3. ↵
    1. Khaw KT,
    2. Wareham N,
    3. Bingham S,
    4. Luben R,
    5. Welch A,
    6. Day N
    . Association of hemoglobin A1c with cardiovascular disease and mortality in adults: the European prospective investigation into cancer in Norfolk. Ann Intern Med 2004;141:413–420pmid:15381514
    OpenUrlCrossRefPubMedWeb of Science
    1. Gerstein HC,
    2. Swedberg K,
    3. Carlsson J,
    4. et al.
    ; CHARM Program Investigators. The hemoglobin A1c level as a progressive risk factor for cardiovascular death, hospitalization for heart failure, or death in patients with chronic heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and Morbidity (CHARM) program. Arch Intern Med 2008;168:1699–1704pmid:18695086
    OpenUrlCrossRefPubMedWeb of Science
    1. Brewer N,
    2. Wright CS,
    3. Travier N,
    4. et al
    . A New Zealand linkage study examining the associations between A1C concentration and mortality. Diabetes Care 2008;31:1144–1149pmid:18299440
    OpenUrlAbstract/FREE Full Text
    1. Levitan EB,
    2. Liu S,
    3. Stampfer MJ,
    4. et al
    . HbA1c measured in stored erythrocytes and mortality rate among middle-aged and older women. Diabetologia 2008;51:267–275pmid:18043905
    OpenUrlCrossRefPubMedWeb of Science
  4. Sarwar N, Aspelund T, Eiriksdottir G, et al. Markers of dysglycaemia and risk of coronary heart disease in people without diabetes: Reykjavik prospective study and systematic review. PLoS Med 2010;7:e1000278
  5. ↵
    1. McNeely MJ,
    2. McClelland RL,
    3. Bild DE,
    4. et al
    . The association between A1C and subclinical cardiovascular disease: the multi-ethnic study of atherosclerosis. Diabetes Care 2009;32:1727–1733pmid:19549732
    OpenUrlAbstract/FREE Full Text
  6. ↵
    1. Selvin E,
    2. Steffes MW,
    3. Zhu H,
    4. et al
    . Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults. N Engl J Med 2010;362:800–811pmid:20200384
    OpenUrlCrossRefPubMedWeb of Science
  7. ↵
    1. Silbernagel G,
    2. Grammer TB,
    3. Winkelmann BR,
    4. Boehm BO,
    5. März W
    . Glycated hemoglobin predicts all-cause, cardiovascular, and cancer mortality in people without a history of diabetes undergoing coronary angiography. Diabetes Care 2011;34:1355–1361pmid:21515847
    OpenUrlAbstract/FREE Full Text
  8. ↵
    1. Winkelmann BR,
    2. Marz W,
    3. Boehm BO,
    4. et al.
    ; LURIC Study Group (Ludwigshafen Risk and Cardiovascular Health). Rationale and design of the LURIC study—a resource for functional genomics, pharmacogenomics and long-term prognosis of cardiovascular disease. Pharmacogenomics 2001;2(Suppl. 1):S1–S73
    OpenUrlCrossRefPubMed
  9. ↵
    1. Haffner SM,
    2. Lehto S,
    3. Rönnemaa T,
    4. Pyörälä K,
    5. Laakso M
    . Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998;339:229–234pmid:9673301
    OpenUrlCrossRefPubMedWeb of Science
    1. Barr EL,
    2. Zimmet PZ,
    3. Welborn TA,
    4. et al
    . Risk of cardiovascular and all-cause mortality in individuals with diabetes mellitus, impaired fasting glucose, and impaired glucose tolerance: the Australian Diabetes, Obesity, and Lifestyle Study (AusDiab). Circulation 2007;116:151–157pmid:17576864
    OpenUrlAbstract/FREE Full Text
  10. ↵
    1. Meigs JB,
    2. Nathan DM,
    3. D’Agostino RB Sr,
    4. Wilson PW
    ; Framingham Offspring Study. Fasting and postchallenge glycemia and cardiovascular disease risk: the Framingham Offspring Study. Diabetes Care 2002;25:1845–1850pmid:12351489
    OpenUrlAbstract/FREE Full Text
  11. ↵
    1. Selvin E,
    2. Crainiceanu CM,
    3. Brancati FL,
    4. Coresh J
    . Short-term variability in measures of glycemia and implications for the classification of diabetes. Arch Intern Med 2007;167:1545–1551pmid:17646610
    OpenUrlCrossRefPubMedWeb of Science
View Abstract
PreviousNext
Back to top
Diabetes Care: 34 (11)

In this Issue

November 2011, 34(11)
  • Table of Contents
  • About the Cover
  • Index by Author
Sign up to receive current issue alerts
View Selected Citations (0)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about Diabetes Care.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Additional Use of Glycated Hemoglobin for Diagnosis of Type 2 Diabetes in People Undergoing Coronary Angiography Reveals a Subgroup at Increased Cardiovascular Risk
(Your Name) has forwarded a page to you from Diabetes Care
(Your Name) thought you would like to see this page from the Diabetes Care web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Additional Use of Glycated Hemoglobin for Diagnosis of Type 2 Diabetes in People Undergoing Coronary Angiography Reveals a Subgroup at Increased Cardiovascular Risk
Guenther Silbernagel, Marcus E. Kleber, Tanja B. Grammer, Bernhard R. Winkelmann, Bernhard O. Boehm, Winfried März
Diabetes Care Nov 2011, 34 (11) 2471-2473; DOI: 10.2337/dc11-1046

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Add to Selected Citations
Share

Additional Use of Glycated Hemoglobin for Diagnosis of Type 2 Diabetes in People Undergoing Coronary Angiography Reveals a Subgroup at Increased Cardiovascular Risk
Guenther Silbernagel, Marcus E. Kleber, Tanja B. Grammer, Bernhard R. Winkelmann, Bernhard O. Boehm, Winfried März
Diabetes Care Nov 2011, 34 (11) 2471-2473; DOI: 10.2337/dc11-1046
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • RESEARCH DESIGN AND METHODS
    • RESULTS
    • CONCLUSIONS
    • Acknowledgments
    • References
  • Figures & Tables
  • Info & Metrics
  • PDF

Related Articles

Cited By...

More in this TOC Section

Original Research

  • A Comparison of Familial and Sporadic Type 1 Diabetes Among Young Patients
  • ACE I/D Polymorphism, Plasma ACE Levels, and Long-term Kidney Outcomes or All-Cause Death in Patients With Type 1 Diabetes
  • Associations Between Exposure to Gestational Diabetes Mellitus In Utero and Daily Energy Intake, Brain Responses to Food Cues, and Adiposity in Children
Show more Original Research

Cardiovascular and Metabolic Risk

  • Association of Metabolic Phenotypes With Coronary Artery Disease and Cardiovascular Events in Patients With Stable Chest Pain
  • Association of Objectively Measured Timing of Physical Activity Bouts With Cardiovascular Health in Type 2 Diabetes
  • Changes in Albuminuria Predict Cardiovascular and Renal Outcomes in Type 2 Diabetes: A Post Hoc Analysis of the LEADER Trial
Show more Cardiovascular and Metabolic Risk

Similar Articles

Navigate

  • Current Issue
  • Standards of Care Guidelines
  • Online Ahead of Print
  • Archives
  • Submit
  • Subscribe
  • Email Alerts
  • RSS Feeds

More Information

  • About the Journal
  • Instructions for Authors
  • Journal Policies
  • Reprints and Permissions
  • Advertising
  • Privacy Policy: ADA Journals
  • Copyright Notice/Public Access Policy
  • Contact Us

Other ADA Resources

  • Diabetes
  • Clinical Diabetes
  • Diabetes Spectrum
  • Scientific Sessions Abstracts
  • Standards of Medical Care in Diabetes
  • BMJ Open - Diabetes Research & Care
  • Professional Books
  • Diabetes Forecast

 

  • DiabetesJournals.org
  • Diabetes Core Update
  • ADA's DiabetesPro
  • ADA Member Directory
  • Diabetes.org

© 2021 by the American Diabetes Association. Diabetes Care Print ISSN: 0149-5992, Online ISSN: 1935-5548.